\
Overview

Radiotherapy uses radiation to kill cancer cells. Radiopharmaceutical therapies (RPTs) are a potentially disruptive class of compounds which merge two stalwarts of cancer therapy – radiology and chemotherapy. RPTs attach a radioactive isotope, or radioisotope, to a targeting molecule, often a chemotherapy agent. The targeting molecule selectively delivers radiation via the radioisotope to cancer cells to destroy tumor tissue while minimizing impact on healthy cells. Recent successes in treatment of metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine cancer have spurred an explosion of commercial development of RPTs aimed at treatment of a broad range of cancers, increasing the need for clinical and administration guidance and standardization.

RPTs can allow common imaging platforms to track their distribution within a patient. An RPT can inform whether the patient is likely to respond to a treatment and allows clinicians to observe what to treat. Treatment effectiveness can be monitored based on measurement of radiation absorbed.

The Precision Dosimetry Imaging Biomarkers (PDIB) project aims to create a harmonized framework for radiation measurement critical for reliable implementation of dosimetry in the clinic. These initiatives are needed for all developing radiopharmaceutical therapies (RPTs) and are expected to inform dosing of RPTs to improve overall survival and quality of life for patients receiving RPT treatment for cancer.

Read What Our Partners Are Saying
Goals

  • Establish radiation measurement procedures and an international academic network of standards laboratories to provide accurate quantification of radiation doses (Phase 1).

  • Optimize and standardize calibration methods to ensure accuracy and consistency of image-derived activity measurements (Phase 1).

  • Develop and validate reproducible RPT dosimetry protocols to enable reliable, harmonized measurements between sites and clinicians (Phase 1).

  • Collect empirical toxicology data in bone marrow and kidneys in prostate and neuroendocrine cancers through dose- escalation studies (Phase 2).

Partners

PUBLIC SECTOR PARTNERS
  • Australian Nuclear Science and Technology Organisation (ANSTO)
  • Belgian Nuclear Research Centre (SCK CEN)
  • National Cancer Institute (NCI)
  • National Physical Laboratory (NPL)
  • National Institute of Standards and Technology (NIST)
  • National Research Council of Canada (CNRC)
  • U.S. Food and Drug Administration (FDA)
MEDICAL SOCIETIES
  • Australian & New Zealand Society of Nuclear Medicine (ANZSM)
  • Society for Nuclear Medicine and Molecular Imaging (SNMMI)
ACADEMIC PARTNERS
  • BC Cancer
  • Institute of Nuclear Medicine
  • Oslo University Hospital
  • Peter MacCallum Cancer Centre
  • University College London
  • University of Alabama at Birmingham
  • University of Iowa
  • University of Sydney
RADIOPHARMACEUTICAL INNOVATORS PARTNERS
  • Eli Lilly and Company
  • Fusion Pharmaceuticals, A member of the AstraZeneca Group
  • Novartis US
  • RayzeBio, a Bristol Myers Squibb Company
BIOTECHNOLOGY COMPANIES
  • ITM
  • Lantheus
  • NorthStar
  • Perspective Therapeutics
  • Telix Pharmaceuticals
START-UPS AND SOFTWARE AND DEVICE DEVELOPERS
  • Capintec, a Mirion Medical Company
  • Hermes Medical Solutions
  • MIM Software, a GE HealthCare Company
  • Rapid
  • RayMed
  • VOXIMETRY
Contact
Althea Lang, PhD, PMP

Senior Project Manager, Translational Science Cancer

[email protected]
Judy Keen, PhD

Director, Translational Science, Cancer

[email protected]
Brianna Mills

Strategic Alliances Officer

[email protected]

Donate

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients